



William J Sandborn

Contact

William J Sandborn

Publications (2)

D'Haens G, Dubinsky M, Kobayashi T, Irving P, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lisssoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands B, LUCENT Study Group, Brand S. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med* 2023; 388:2444-2455.

Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus E, Ostad-Saffari E, Scalori A, Oh Y, Tole S, Chai A, Pulley J, Lacey S, Sandborn W, HICKORY Study Group. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. *Lancet Gastroenterol Hepatol* 2021; 7:128-140.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch